---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-079824"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-07-21T12:30:30+00:00"
generated_at: "2026-07-21T12:35:12.521872+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics launches partnering process for late-stage cardiac critical care assets

## Summary
- Portfolio aligned into three pillars: Pre-Operative Safety (frunexian), Orphan Regulatory Acceleration (tecarfarin), Post-Operative Shield (CAD-1005).
- Phase 2 CAD-1005 data showed >25% absolute reduction in thrombotic events in heparin-induced thrombocytopenia patients.
- Seeking out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets.
- Also advancing oral 12-LOX inhibitor CAD-2000 for chronic cardiorenal inflammatory and thrombotic indications.

## SEC filing metadata
- accession: 0001213900-26-079824
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-07-21T12:30:30+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026079824/0001213900-26-079824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026079824/ea0298669-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-079824
- JSON: https://secwatch.observer/filing/0001213900-26-079824.json
- Plain text: https://secwatch.observer/filing/0001213900-26-079824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.